ROCKVILLE, MD and SHENZHEN, CHINA, May 14, 2024—HighTide Therapeutics, Inc. , a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases, announced today that it presented at the Abu Dhabi Global Healthcare Week –Health Leaders Forum. Dr. Liping Liu, Founder, CEO and Chairperson of HighTide Therapeutics (“HighTide”), was invited to speak on a panel discussion regarding the impact of AI on drug R&D and healthcare. On the panel, Dr. Liu was joined by:

    · Sir Patrick Vallance, Strategic Counselor; Former UK Government Chief Scientific Adviser, Tony Blair Institute

    · Dr. Alex Zhavoronkov, Chairman of the Board, Executive Director & CEO, Insilico Medicine

    · Sergey Young, Co-founder, Longevity Growth Fund

    · Charles Conn, Co-founder & Partner, Monograph (moderator)

The Health Leaders Forum took place on May 13-15, 2024 in conjunction with the Abu Dhabi Global Healthcare Week (“ADGHW) conference, hosted by the Abu Dhabi Department of Health. ADGHW will focus on the issues and opportunities driving healthcare services, investments, and innovation to solve the most important global health challenges. The event will gather healthcare leaders, policymakers, stakeholders and disruptors from around the world to address global perspectives and challenges, with the ultimate aim of ‘Accelerating the Future of Global Healthcare.’

About HighTide Therapeutics

HighTide Therapeutics, Inc.  is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer

The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change considering future developments.

For more information, please visit www.hightidetx.com.

Contact: pr@hightidetx.com